Note: 23andme's revenues are gauged from an analysis of company filings.
23andme has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
August 2, 2018
Complete list of funding rounds and total amounts in the Company Report
23andme's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
23andme Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that 23andme is developing and marketing.
23andme's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
MEET YOUR GENES Providing scientific analysis and informational reports based upon results of laboratory testing in the field of genetics; providing online computer databases featuring information based on aggregated results of genotyping; application service provider (ASP) featuring software for providing access to multiple databases that contain aggregated results of genotyping; application service provider (ASP) featuring software for use in data management, data storage, data analysis, report generation, user identification, and membership identification, all in the fields of genetics and genetic testing; scientific research in the fields of genetics, genetic testing, genetic screening, genotyping, phenotyping, molecular analytics
LIVE IN THE KNOW Genetic identity testing for medical and ancestral information purposes and providing scientific analysis and informational reports based on results from laboratory testing in the fields of genetics and genotyping and ancestry
THIS WEEK IN DNA Creation and development of educational and entertainment audio visual content in the field of genetics and genetic testing
Patent applications show 23andme's intellectual property,
its current capabilities and future direction.
23andme has applied for 12 patents since 2009.
23andme's most recent patent was filed in September 2016 for Genome Sharing.Sharing data is disclosed. In some cases, sharing data includes receiving a request to share data from a first account to a second account, receiving an indication of a plurality of first account profiles associated with the first account to share with the second account, and establishing sharing from the plurality of first account profiles to the second account, wherein sharing comprises the second account having read access to a subset of nonpublic data associated with the plurality of first account profiles.
Complete list of patent applications
Determine whether 23andme grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof 23andme is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: 23andme vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as 23andme, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as 23andme and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.